Comparing the current results to its competitors, Precision Biosciences Inc reported Revenue increase in the 1 quarter 2026 by 37272.41 % year on year, while most of its competitors have experienced contraction in revenues by -42.2 %, achieved in the same quarter.
Due to outstanding performance in Overall company, revenue grew by 37272.41 % Precision Biosciences Inc improved its market share, to approximately 2.8 %.
August 1, 2024
Precision BioSciences: Pioneering Gene Editing Advancements With Financial Growth and Expanding Expertise DURHAM, N.C. Precision BioSciences, Inc. (Nasdaq: DTIL), a vanguard in the field of gene editing, has recently announced its second-quarter financial results for 2024, coupled with strategic advancements in its groundbreaking research initiatives. Utilizing its proprietary ARCUS platform, Precision BioSciences is at the forefront of developing innovative in vivo gene editing therapies, aimed at sophisticated genetic modifications such as gene elimination, insertion, and excision.In a reflection of robust progress made during the first half of 2024, the company underscored their commitment to advancin...
July 1, 2024
Precision BioSciences Expands its Presence and Advances Hepatitis Research with New Appointments and Clinical DataDURHAM, N.C. - Precision BioSciences, an advanced gene editing company utilizing its proprietary ARCUS platform, is making significant strides in the field of gene editing therapies. The company recently announced its addition to the Russell Microcap Index, a prestigious milestone that highlights its growth and potential in the market. This accomplishment follows the conclusion of the 2024 Russell indexes annual reconstitution.In addition, Precision BioSciences has expanded its Hepatitis Scientific Advisory Board by welcoming two world-class clinical investigators, Mark Sulkowski, M.D., and Jorda...
June 5, 2024
Precision BioSciences, an advanced gene editing company utilizing its novel ARCUS platform, has recently made significant strides in the development of gene editing therapies. The company will be presenting preclinical safety data for its PBGENE-HBV clinical candidate at the European Association for the Study of the Liver (EASL) Congress, emphasizing the unique capabilities of ARCUS to efficiently and precisely eliminate specific genes.During the presentation, Precision BioSciences will showcase the differentiated ability of ARCUS to achieve efficient, durable, and targeted elimination edits, demonstrating its potential as a groundbreaking treatment for chronic hepatitis B (HBV). This development holds great...
May 13, 2024
Precision BioSciences Reports First Quarter 2024 Financial Results and Provides Business UpdateDURHAM, N.C. - Precision BioSciences, Inc. (Nasdaq: DTIL), a pioneering gene editing company, announced its financial results for the first quarter ended March 31, 2024, and provided an update on its business activities. The company, utilizing its innovative proprietary ARCUS platform, aims to develop in vivo gene editing therapies for advanced gene modifications, such as gene elimination, insertion, and excision.In this year, Precision BioSciences is primarily focused on strong execution, as it advances its wholly owned projects targeting the Hepatitis B virus (HBV) and other sophisticated gene editing application...
May 7, 2024
In the dynamic world of genetic science, a significant breakthrough underpins the treatment of a rare inherited disorder, Ornithine Transcarbamylase (OTC) deficiency, as breakthrough innovator, Precision BioSciences, Inc., announces the receipt of Fast Track designation for their partner, iECURE’s program, ECUR-506 from the U.S. Food and Drug Administration (FDA). This pioneering stride provides a beacon of hope for those afflicted with this infrequent but devastating condition.Precision BioSciences positions itself as an avant-garde gene editing firm based in Durham, N.C. It leverages its unique and proprietary ARCUS platform to design in vivo gene editing therapies for intricate gene modifications, encom...
May 1, 2024
The company s ground-breaking preclinical data from its pipeline candidate, PBGENE-HBV, for chronic hepatitis B (HBV) treatment will be the core focus of this forthcoming presentation. The exceptional data pointing towards a breakthrough in HBV treatment will deliver a potentially better solution for millions suffering from the disease across the globe.Chronic hepatitis B, a progressive condition, represents significant health problems worldwide, with about 257 million people living with the disease according to World Health Organization reports. In this context, Precision BioSciences PBGENE-HBV could prove to be a real game-changer, coming as gladdening news to millions of patients worldwide who could bene...
MeiraGTx Holdings Plc is a biotechnology company focused on developing gene therapies for inherited and acquired diseases. They leverage their proprietary technology to develop and commercialize innovative treatments that address unmet medical needs.
Lexeo Therapeutics Inc is a biotechnology company focused on developing advanced gene therapies for the treatment of genetic disorders. Their business model revolves around leveraging cutting-edge technology and scientific expertise to develop innovative gene therapies that address significant unmet medical needs. They aim to bring these therapies to market through strategic partnerships and collaborations with pharmaceutical companies and academic institutions.
LogicBio Therapeutics Inc is a biotechnology company that focuses on developing and commercializing gene editing technology to treat rare genetic diseases.
Sources:
Precision Biosciences Inc’s official press releases and regulatory filings; CSIMarket.com’s market research; and the financial filings and press releases of other companies cited in this report.
Updated on:
Focus of this report: publicly traded companies.
For your research, we’ve provided 10 tables on Precision Biosciences Inc versus competitors, including market share analysis.
You can find them in the navigation menu under Competition.
To download the tables, please subscribe.
Intraday data delayed per exchange requirements. All quotes are in local exchange time. Intraday data delayed 15 minutes for Nasdaq, and other exchanges. Fundamental and financial data for Stocks, Sector, Industry, and Economic Indicators provided by CSIMarket.com
Disclaimer: Information provided by CSIMarket.com is for informational purposes only and does not constitute investment advice, recommendation, or solicitation to buy or sell any security.
